Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03074357 · ClinicalTrials.gov registry record
Urine, DNA and Clinical Information Collection From Patients With Alport Nephropathy.
A clinical trial of Alport Nephropathy, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 68
- Enrollment target
- 1
- Study location
NCT03074357: Completed study of Alport Nephropathy, sponsored by Novartis Pharmaceuticals.
NCT03074357 is a study of Alport Nephropathy that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 68 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03074357, a study of Alport Nephropathy, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
This biomarker study is a follow-up to CPLATFRM2201. The goal of CBASICHR0005 is to collect another urine sample, interval clinical information, and an optional DNA sample from as many of the original 80 patients as possible. This new information will transform the data obtained in PLATFRM2201 from a cross-section to a temporal profile, which will (a) further enable the identification of biomarkers predictive of faster progression, and (b) satisfy the FDA's recommendation to perform "natural history studies" in rare diseases.
Primary Outcome
Urine levels of biomarkers, corrected for urine creatinine, in Alport subjects stratified by magnitude of proteinura.
Conditions Studied
Study Locations (1)
Minnesota
- Novartis Investigative Site - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2017-04-04 |
| Est. Completion | 2018-03-23 |
What the finished NCT03074357 record still lists
NCT03074357 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 68 participants, a relatively small participant target.
The record links to 1 condition, with Alport Nephropathy appearing as the primary indexed condition, and to 0 interventions.
NCT03074357 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03074357 about?
NCT03074357 is a clinical study titled "Urine, DNA and Clinical Information Collection From Patients With Alport Nephropathy.". This biomarker study is a follow-up to CPLATFRM2201. The goal of CBASICHR0005 is to collect another urine sample, interval clinical information, and an optional DNA sample from as many of the original 80 patients as possible. This new information will transform the data obtained in PLATFRM2201 from ...
What is the current status of trial NCT03074357?
This trial is currently completed. The enrollment target is 68 participants. The study started on 2017-04-04. Estimated completion is 2018-03-23.
What conditions does trial NCT03074357 study?
This clinical trial studies the following conditions: Alport Nephropathy.
Who is sponsoring clinical trial NCT03074357?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03074357 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI